A once-weekly GLP-1 RA

A once-weekly GLP-1 RA

When metformin alone is no longer enough, think Ozempic®

Ozempic® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.1

Where is Ozempic® publicly covered?

Explore resources available to you and your patients

Want to learn more, request samples, or have a question?

Contact Us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:

Main fax number:
Toll-free fax number: